Nutriband Inc Warrant 2021- on Nutriband NTRBW 深 沪
已收盘 04-02 16:00:00 美东时间
1.15
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.15
- 总市值 0
- 52周最高 4.50
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.80
- 委 比 -31.03%
- 总股本 --
- 历史最高 9.07
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.1885
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nutriband Selects Commercial Brand Name For Abuse-Deterrent Fentanyl Patch; Prepares FDA And Global Trademark Submissions
Nutriband has selected the commercial worldwide brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit to the FDA for approval per FDA Guidance.Nutriband partnered with Brand
03-31 04:18
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Nutriband Inc. has chosen a global commercial brand name for its abuse-deterrent fentanyl transdermal system and will submit it to the FDA and other regulatory agencies for approval. The company partnered with Brand Institute, Inc., a leader in pharmaceutical brand name development, to ensure the name is safe, unique, and compliant with regulations. The product uses Nutriband’s AVERSA™ technology, designed to prevent abuse and misuse of transderm...
03-30 20:05
Nutriband Gets Approval To Sell Kinesiology Tapes In Costa Rica
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company's line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company's exclusive
03-18 19:08
Nutriband Strikes Distribution Deal With Innomedica For AVERSA Fentanyl
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products
02-17 20:30
Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. reported on 2025 achievements including advancing their AVERSA™ Fentanyl patch towards commercialization, securing patents, and enhancing shareholder value through strategic moves like selling a subsidiary and issuing preferred stock dividends. The company also joined four prominent indexes and anticipates reduced stock volatility as warrants from their 2021 IPO expire in 2026. AVERSA™ aims to be the world's first abuse-deterrent o...
2025-12-31 12:00
Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
US designates illicit fentanyl as a weapon of mass destruction due to its severe dangers. However, FDA-approved prescription fentanyl patches remain critical for opioid-tolerant patients with severe chronic pain. Nutriband Inc., in collaboration with Kindeva, is developing AVERSA™ FENTANYL, the first abuse-deterrent opioid patch, incorporating aversive agents to prevent misuse and accidental exposure. The technology aims to improve safety while e...
2025-12-18 12:00
Nutriband Founder Gareth Sheridan Returns as CEO to Lead Company Toward 2026 NDA Filing, Serguei Melnik Steps Down
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei
2025-10-27 19:09
Nutriband Co-Founder Gareth Sheridan Returns as CEO
Nutriband Inc. announced that founder Gareth Sheridan has returned as CEO, succeeding Co-Founder Serguei Melnik who led the company from August 10 to October 27. Sheridan will guide Nutriband toward the 2026 NDA filing for AVERSA Fentanyl, an innovative abuse-deterrent opioid patch designed to reduce misuse and accidental exposure. Targeting annual U.S. sales of $80–200 million, AVERSA Fentanyl addresses a global need for safer pain management. T...
2025-10-27 11:00
Nutriband Signs Agreement Brand Institute For AVERSA Fentanyl, Plans To Commercialize Abuse-Deterrent Opioid Patch
Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system.Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and
2025-10-10 19:05
Nutriband Reports 50.87% Revenue Growth, $6.9M Cash; Advances AVERSA Fentanyl Toward NDA With No Phase 2/3 Trials Required
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the
2025-09-10 21:20
